

Michigan Pharmacy and Therapeutics Committee
Meeting of September 11, 2007
Kellogg Center, Michigan State University, East Lansing Michigan
DRAFT Minutes DRAFT

Introductions

The following Committee members were in attendance: Drs. Nedd, Fiechtner, Dillon, Arend, Van Loo, Dake, Bradley, Rogers, Perri, Dorfman. Dr. Inman had an excused absence. Others in attendance: Debera Eggleston, MD, Karen Jonas, RPh, DUR Board, Trish O'Keefe, RN, George Baker, MD, Thomas Welch, Sean Bodell, Jacqueline Coleman, Annette Paul, RPh, Susan Moran, and Brenda Schultz, Pharmacy Student, Ferris State University

Approval of Minutes of June 5, 2007 Meeting

The draft minutes were approved as written

New Drug Reviews

Following review and discussion, the Committee recommends to the Department:

Pylera: Add to the MPPL without prior authorization

Tekturna: Add to the MPPL and the PDL; set up another class in the Cardiac drug classes in the PDL, termed "Direct Renin Inhibitor"; add with Prior Authorization

Soliris: This is a physician service and would be covered as a medical benefit

Brovana: Add to the MPPL and to the PDL in the class "Beta Adrenergics, Long Acting" with Prior Authorization

Torisel: This is a physician service and would be covered as a medical benefit

Letairis: Add to the MPPL without Prior Authorization

Line Extensions

Following review and discussion, the Committee recommends to the Department:

Seroquel XR: Add to the MPPL without Prior Authorization

Eth-Oxydose 20mg/ml solution: Add to the MPPL and PDL; there is a MAC on oxycodone solution, 20mg/ml; follow MAC rules for payment

Review of PDL Classes

Following review and discussion the Committee recommended the following to the Department

Diabetes:

Amylin Analogs

No change to current classification

Secretin Mimetics

No change to current classification

Insulins, Basal

No change to current classification

Insulins, Rapid Acting

No change to current classification

Insulin Mixes

No change to current classification

Insulins, Traditional

No change to current classification

Insulins, Inhaled

No change to current classification

Oral Hypoglycemics-Alpha Glucosidase Inhibitors

No change to current classification

Oral Hypoglycemics-Biguanides

No change to current classification
Remove prior authorization from the 750mg strength Metformin XR
 Oral Hypoglycemics-Combinations
No change to current classification
 Oral Hypoglycemics-DPP4 Inhibitors
No change to current classification
 Oral Hypoglycemics-Meglitinides
No change to current classification
 Oral Hypoglycemics-2nd Generation Sulfonylureas
No change to current classification
 Oral Hypoglycemics-Thiazolidinediones
No change to current classification at this time; the workgroup will closely monitor any further clarification from the FDA

Gastrointestinal

 Nausea Agents, Oral
No change to the current classification of these drugs
The workgroup did recommend having the DUR Board review the expanding use of Marinol to validate it is being used for its licensed indications
 Substance P Receptor Agonist
No change to the current status of this drug
 Proton Pump Inhibitors
No change to the current classification of these drugs
Maintain the high dose clinical edit currently in policy
Consider review of this class as a DUR Board project
 5HT4 Agonists
Remove this class from the PDL as this drug has been removed from the market
 Laxatives, New Generation
No change to the current status of this drug

Ophthalmics

 Glaucoma-Alpha-2 Adrenergics
No change to the current classification of medications
 Glaucoma-Beta Blockers
Add Istalol brand of timolol to the list of products requiring PA
No other changes to the drug listings
 Glaucoma-Prostaglandin Inhibitors
Add Travatan Z along with Travatan to the list of drugs available without PA
 Glaucoma-Carbonic Anhydrase Inhibitors
No change to the current classification of medications
 Ophthalmic Antihistamines
Add Pataday to Patanol as available without PA
Remove Zaditor from the list as the drug has become an over the counter product
 Ophthalmic Fluoroquinolones
No change to the current classification of the drugs
 Ophthalmic Mast Cell Stabilizers
No change to the current classification of the drugs
 Ophthalmic NSAIDs
No change to the current classification of the drugs

Miscellaneous

 Osteoporosis Agents: Bisphosphonates
No change to the current classification of the drugs
 Osteoporosis Agents: Other

No change to the current classification of the drugs
Osteoporosis Agents: SERMs

No change to the current classification
Serotonin Receptor Agonists

No change to the current classification of the drugs
Urinary Antispasmodics

No change to the current classification of the drugs
Generic oxybutinin extended release should still continue with prior authorization
Topical Immunomodulators

No change to the current classification of these drugs
Electrolyte Depleters

No change to the current classification of these drugs
Alpha Blockers for BPH

No change to the current classification of these drugs
Agents for Multiple Sclerosis

No change to the current classification of these drugs
Non-Ergot Dopamine Receptor Agonists

No change to the current classification of these drugs
Biologic Immunomodulators

No change to the current classification of the drugs
Note was made of the added FDA indications for these pharmaceuticals
Hematopoietic Agents

No change to the current classification of the drugs
Low Molecular Weight Heparins

No change to the current classification of the drugs
The workgroup recommends the Department review these agents through DUR for
appropriateness of use
Combination Benzoyl Peroxide and Clindamycin

No change to the current classification of these drugs
Otic Quinolones

No change to the current classification of these drugs

Public Comment

The following persons made comment to the Committee
Christine Sproles, PharmD, Sepracor, Lunesta
Paul Miner, PharmD, Novartis, Tekturna
Dr. Steven Stryk, , Veramyst
Oren Mason, MD, JNJ, Concerta
L. Jean Dunegan, MD, Pfizer, Celebrex
Dr. Terry Dickson, Shire, Vyvanse
Jeffrey Olson, MD, Gilead, Letairis

Next meeting: Tuesday, December 4, 2007, 6 PM, Kellogg Center